Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | PPARA | Q07869 | 5/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865652 | 0.86 | CAPN1 (0.61) | CAPN1CTSB | |
| SCHEMBL2369340 | 0.86 | CAPN1 (0.61) | CAPN1CTSB | |
| SCHEMBL3292711 | 0.86 | CAPN1 (0.61) | CAPN1CTSB | |
| SCHEMBL3719359 | 0.85 | CAPN1 (0.62) | CAPN1FFAR1PPARGPPARACTSB | |
| SCHEMBL20529415 | 0.85 | CAPN1 (0.62) | CAPN1FFAR1PPARGPPARACTSB | |
| SCHEMBL18262577 | 0.84 | LDHA (0.57) | CAPN1ACACBPPARGPPARACTSB | |
| SCHEMBL16932220 | 0.83 | CAPN1 (0.52) | CAPN1CTSB | |
| SCHEMBL1286249 | 0.80 | ACACB (0.50) | CAPN1ACACBPPARGPPARACTSB | |
| SCHEMBL2545520 | 0.79 | CAPN1 (0.62) | CAPN1 | |
| SCHEMBL17923806 | 0.79 | ACACB (0.69) | FFAR1ACACBPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989480-B2 | Aryl amino acid derivatives as inhibitors for treating inflammation | DECODE GENETICS EHF (IS) | 2011-08-02 | — | — | US | disclosed |
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | LTA4H, LTB4R2, LTB4R | CAPN1 4026/4885FFAR1 338/4885ACACB 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.